Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Monocytes from male patients with ankylosing spondylitis display decreased osteoclastogenesis and decreased RANKL/OPG ratio

Full text
Author(s):
Caparbo, V. F. [1] ; Saad, C. G. S. [1] ; Moraes, J. C. [1] ; de Brum-Fernandes, A. J. [2] ; Pereira, R. M. R. [1]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Hosp Clin HCFMUSP, Rheumatol Div, Bone Metab Lab, Av Dr Arnaldo 455, 3 Andar, Sala 3193, BR-01246903 Sao Paulo, SP - Brazil
[2] Univ Sherbrooke, Fac Med & Sci Sante, Serv Rhumatol, Dept Med, Sherbrooke, PQ - Canada
Total Affiliations: 2
Document type: Journal article
Source: OSTEOPOROSIS INTERNATIONAL; v. 29, n. 11, p. 2565-2573, NOV 2018.
Web of Science Citations: 3
Abstract

aSummaryThe present study investigates the osteoclastogenic capacity of peripheral blood mononuclear cells (PBMCs) in male patients with ankylosing spondylitis (AS). We demonstrated that monocytes from these patients display a lower capacity to generate osteoclasts compared to cells from healthy controls, and osteoclastogenesis was negatively correlated with disease duration.IntroductionAnkylosing spondylitis (AS) is a disease characterized by new bone growth that leads to syndesmophyte formation but AS patients frequently present with low bone mineral density/fractures. Osteoclastogenesis in AS patients is poorly studied and controversial. The aim of this study is to determine if the osteoclastogenic capacity of PBMCs is different in AS patients compared to controls and the relationship between osteoclastogenesis and clinical/laboratory parameters.MethodsPBMCs from 85 male AS patients and 59 controls were tested for CD16+ cells and induced to differentiate into osteoclasts over 3weeks in vitro. Serum levels of RANKL, osteoprotegerin (OPG), C-terminal telopeptide of type I collagen (CTX), and amino-terminal pro-peptide of type I collagen (P1NP) were also evaluated.ResultsPBMCs from AS patients had fewer CD16+ cells and produced fewer osteoclasts compared to controls. Apoptosis occurred less frequently in osteoclasts obtained from AS patients than in osteoclasts from the controls. A lower RANKL/OPG and CTX/P1NP were observed in AS patients compared to controls. AS patients taking NSAIDs presented no difference regarding the number of OCs produced and the percentage of CD16+ cells compared to controls. However, patients taking TNF inhibitors (TNFi) presented lower OC numbers than controls. A negative correlation was demonstrated between the number of osteoclasts generated from PBMCs of AS patients and disease duration.ConclusionMonocytes from male AS patients display a lower capacity to generate osteoclasts in vitro compared to cells from controls. Osteoclastogenesis was negatively correlated with disease duration. This finding supports the idea that osteoclasts play a role in the physiopathology of bone disease in AS patients. (AU)

FAPESP's process: 11/23781-2 - Role of osteoclastogenesis and osteoclasts activation in patients with ankylosing spondylitis
Grantee:Rosa Maria Rodrigues Pereira
Support Opportunities: Regular Research Grants